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agricultural biotechnology has its roots in Europe. The basic technology–Agrobacterium 
tumefaciens-mediated gene transfer into plants—was discovered and developed by Jeff 
Schell and Marc van Montagu in Cologne, Germany, and Ghent, Belgium. Despite 
these successful research activities and patenting of the technology, efforts to put these 
inventions into practice and launch profitable products on the European market were 
unsuccessful due to fierce and continued protests from non-governmental organizations 
(NGOs) prejudicing the general public and political leaders against genetically modified 
(GM) plants. 
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Commercialization of Agbiotech Products 




The EU moratorium on approval of GM plants in 1998 was a 
particularly serious blow.
The first commercial cultivation of GM plants took place in 995 in the United States. 
Since then, the industry has seen double-digit growth every year, but only outside of Eu-
rope. The EU moratorium on approval of GM plants in 998 was a particularly serious 
blow. Most biotechnology companies, especially those financed by venture capital, went 
out of business, lacking strategies for surviving a 6-year-period without launching products. 
Even large multinationals fell victim, and had to merge or were sold to competitors to 
increase shareholders’ values. Small and medium-sized companies survived only if they 
had products other than GM plants in their portfolios and with global markets. 
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Successful Business Strategy 
Phytowelt Greentechnologies offered services and contract research in addition to de-
veloping products for industry and consumers. Our main technologies—the proprietary 
genetic marker system IStr, patented genes to improve plants and tissue-culture tech-
nologies such as somatic hybridization—led to projects with ornamental, food and fodder 
plants. Furthermore, we improved procedures for the production of phytopharmaceuticals 
and platform chemicals for our clients in the chemical and pharmaceutical industries. 
The success and steady development of the company are based on an international 
orientation and embracement of globalization since the beginning. Clients in Japan, New 
Zealand, Canada, United States and Europe are proof of this strategy. another critical 
factor was the self-sustained financing by private shareholders, assignments and contracts. 
Grants from public institutions were used to implement new technologies. 
Political Obstacles
Nowadays, the European biotech landscape shows an uneven distribution of companies, 
with concentrations along the rhine and the river Thames as well as uneven application. 
Medical and pharmaceutical biotech companies outnumber, by a factor of five, those with 
an agricultural orientation. 
Besides the lack of consumer acceptance, absence of consistent and reliable legislation 
prevent commercialization of GM products in Europe. The discussion revolves around 
thresholds, labelling, traceability, monitoring, coexistence, admixture, liability and bio-
patents without reaching firm conclusions to provide a legislative framework. Instead, 
more research has been demanded to prove the safety of GM crops, serving to postpone 
their introduction. Interest on the part of the industry to conduct appropriate research 
has declined in recent years. The number of field trials (Figure ) reached its peak in 
997/998, and since then has decreased significantly. a small increase in 006 may 
indicate a turning point, but it is too early to be certain.
Spain leads the current EU member states with 53,000 ha planted to GM crops in 
005, and with an increase in 006. romania, which will become an EU member in 
007, has an even greater area, of GM soybean. However, because the cultivar is not 
approved within the EU, its cultivation will be forbidden once romania enters EU-5. 
Three other European states, Germany, France and the Czech republic, together had 
around ,000 ha of GM crops in 005. This probably hit the 0,000-ha threshold in 
006, largely because of ten-fold increases in France and the Czech republic; Germany 
planned only a doubling to around 900 ha. 
More research has been demanded to prove the safety of GM 
crops, serving to postpone their introduction.
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End of the Moratorium
a turning point occurred in 004 when the EU ended its moratorium and approved 
importation of GM corn. In 005, Germany turned its attention to GM after the Green 
party failed to win re-election in their last two strongholds, the NrW state government 
and the federal government of Germany; three varieties of GM corn were approved for 
cultivation within the first 00 days of the new federal government. Coincidentally, 
Phytowelt sold the first license of its proprietary parthenocarpy technology to a US seed 
company. But the general situation in Europe is unchanged: to stay in business, produce 
either non-GM products (Figure ) or  non-food value-added products like monoterpenes 
(Figure 3). This is also the strategic line of the European Commission. In their Plants for 
the Future program, the emphasis is on bioenergy and biobased chemicals to promote 
development of a biobased economy. Their decade-long timeframe indicates that even in 
Figure . The number of field trials of GM plants increased steadily until 997. The 
European Commission’s 998 moratorium, preventing commercialization of GM 
plants, adversely affected r&D. 
In the European Commission’s Plants for the Future program, 
the emphasis is on bioenergy and biobased chemicals to promote 
development of a biobased economy.
Welters 9
the Commission no one expects short-term implementation of the technology in Europe. 
and to avoid the term “genetic engineering” “precision breeding of renewable resources” 
has become the fashionable, politically correct term. 
Industrial Plant Biotechnology
a fairly new trend, but not a new industry, is so-called “white” or “industrial” biotechnol-
ogy in Europe. Because of the success of some European companies (e.g. DSM, Novozymes, 
BraIN), this field is considered as more promising than biotechnology of plants for 
food and feed. In the beginning, companies tried to avoid being connected with genetic 
engineering of plants. But it is becoming accepted that industrial biotechnology needs 
to be combined with plant biotechnology to fully exploit its potential. 
Instead of using agriculture only as a source of feedstock for fermenters in the form 
of sugar and other low-value commodities, it was realized that plants can deliver a whole 
range of complex chemical entities. Precursors for steroid hormones and cancer medication 
(e.g. taxol) for the pharmaceutical industry and polymers like caoutchouc, a polyterpene, 
for the rubber industry are already being delivered by plants. Mint plants can produce a 
Figure . Non-genetically engineered, non-food products currently have the best 
chances of success on the European market. Despite the end of the moratorium, GM 
plants are still underrepresented.
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Figure 3. The biosynthesis of menthol as an example of the production of platform 
chemicals in mint plants exploiting their biodiversity for the sustained production of 
chemicals; a, b, c and d are known enzymes of the biosynthetic pathway that can be 
genetically modified to direct the production of a particular monoterpene.
whole range of monoterpenes depending on the variety, thus biodiversity may be exploited 
to increase the use of renewable resources for sustained production of chemicals (Figure 
3). With genetic engineering, plant biotechnology can combine the primary produc-
tion of agriculture and the conversion technology in fermenters to shorten the process 
and reduce costs. By providing higher concentrations of basic precursors, such plants 
will improve fermentation processes. Due to removal of contaminating by-products by 
inhibiting their synthesis in planta, the higher purity of products from GM plants will 
secure their usefulness to the chemical industry. 
Financial aspects
Encouraging signals from the technological side are supported by recent news of mergers 
and acquisitions. Plant biotechnology companies are again the target for multinational 
corporations to improve their pipelines, e.g. BaYEr incorporated Icon Genetics, BaSF 
bought CropDesign in Belgium, and Biolex (USa) acquired Lemnagene (France). The 
formation of Phytowelt Greentechnologies was a merger of equal partners, Phytowelt and 
Greentec, the latter a spin-off of the Max-Planck-Institute for Plant Breeding research 
Plant biotechnology companies are again the target for 
multinational corporations to improve their pipelines.
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Figure 4. GO indicating modern, 
 innovative genetic engineering 
to improve a product labelled 
 according to quality standards 
 defined by the academic and 
 industrial communities.
in Cologne. The increased interest in plant biotechnology from the financial community 
is also shown in a new round of financing for Novoplant, Germany: they raised 3 mil-
lion euros. and new companies are being founded, such as Solucel, a combined effort 
involving Finnish and Belgian governmental institutions.
Conclusion
These examples show that biotechnology is on the rise again in Europe. Instead of being 
paralyzed by the scaremongering of anti-GMO-activists, we should spread the good news. 
There are enough examples to show the benefits of applying genetic engineering of plants 
and thereby convince the general public. We 
have only to inform people correctly and 
constantly about the progress and the benefits 
of this new technology. Millions of farmers 
worldwide cannot be wrong!
Labelling should be mandatory for prod-
ucts improved by genetic engineering (Figure 
4) to show that we are proud of the technolo-
gy and convinced of its benefits. Conferences 
like NaBC’s and aBIC’s are important and 
supporting them helps to improve acceptance 
and distribution of this beneficial technology. 
NaBC 9 will convene in Brookings, South 
Dakota, May –4, 007, and aBIC007 
in Calgary, September 3–6, 007.
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aFter studying chemistry, biochemistry and food 
chemistry in Germany, Peter Welters spent 4 years at the 
Max-Planck-Institute for Plant Breeding research, there 
obtaining his Diploma and PhD. He worked in Jeff Schell’s 
group on promoter control in the legume/rhizobia nitrogen-
fixing symbiosis. after 3 years at the University of California, 
San Diego, in the laboratories of Maarten Chrispeels and 
Scott Emr, researching protein-transport regulation in plants and yeasts, he was 
chosen as head of the Production of Pharmaceutical Proteins in Plants project in 
rouen, France. 
Dr. Welters’s innovative ideas led to the foundation of Biotechnology and 
Molecular Biology, which became Phytowelt GmbH in 998. Four years later, 
he became CEO of Greentec GmbH, a spin-off company of the Max-Planck-
Institute, founded by Schell, Klaus Hahlbrock, Frederico Salamini, and Heinz 
Saedler.
Since January 006, Welters has been CEO of Phytowelt Greentechnologies 
GmbH, a fusion of Greentec and Phytowelt, located in Nettetal (head office) 
and Cologne (r&D). The company offers laboratory and know-how services 
in agricultural biotechnology, e.g. somatic hybridization, tissue culture, marker 
technologies, contract studies and project coordination. He is also a board member 
of the aBIC Foundation, Canada, and BioCologne eV, Germany.
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